Key result
Compound 10 selectively inhibited iNOS with an IC50 of 0.428 μM and an excellent selectivity over eNOS (>2300-fold), without affecting endothelial NO-mediated vasodilation ex vivo.
Compound 10 is a novel, highly selective iNOS inhibitor that demonstrates potent in vitro activity and preserves eNOS function ex vivo, offering a potential scaffold for treating conditions characterized by iNOS overactivity.
Answers are grounded in this paper and cite their sources.
No clinical adoption warranted yet; hypothesis-generating for selective iNOS inhibitor scaffolds in iNOS-overactive states.
N-[(3-Aminomethyl)benzyl]acetamidine derivatives were synthesized and in vitro evaluated as inhibitors of the inducible isoform of nitric oxide synthase (iNOS). Because of the high potency of action and the excellent selectivity over the endothelial nitric oxide synthase (eNOS), compound 10 was ex vivo evaluated on isolated and perfused resistance arteries. The results confirm that compound 10 selectively inhibits the iNOS, without affecting the endothelial isoform. The outcome of the docking studies showed that the hydrophobic interaction is the driving force of the binding process, especially for iNOS, where the binding pocket is characterized by a significant lipophilic region.
No takes yet. Share an insight, caveat, or question.
Maccallini et al. (2015) studied this question. Compound 10 vs. eNOS / 1400W / L-NAME was evaluated on iNOS inhibition (IC50) (IC50 0.428 μM). Compound 10 selectively inhibited iNOS with an IC50 of 0.428 μM and an excellent selectivity over eNOS (>2300-fold), without affecting endothelial NO-mediated vasodilation ex vivo.
Synapse has enriched 10 related papers. Consider them for comparative context: